Navigation Links
Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins

WALTHAM, Mass. and KANSAS CITY, Mo., March 13 /PRNewswire/ -- Proteon Therapeutics, Inc. (, announced today that a key patent has been issued by the European Patent Office. The patent (No. 1220830) covers the use of a class of proteins known as elastases for dilating arteries and veins in humans. This follows the issuance of related United States patents in June and December of 2006. Proteon Therapeutics owns all of these patents by assignment from Johns Hopkins University, where the underlying invention was made by F. Nicholas Franano, M.D.

"We are very pleased that the European Patent Office has joined with their U.S. counterparts in recognizing the fundamental breakthrough described in this patent," said Dr. Franano, Founder and Chief Scientific Officer of Proteon Therapeutics.

"The issuance of this patent further strengthens and broadens Proteon's elastase vasodilation franchise," said Timothy Noyes, President and Chief Executive Officer of Proteon Therapeutics. "With this patent in hand, Proteon Therapeutics can continue the global development of PRT-201, our lead drug candidate," added Noyes.

The law firm Dechert LLP, oversaw patent prosecution in Europe while the firm of Fried, Frank, Harris, Shriver & Jacobson LLP, served as lead U.S. patent counsel.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, MA, and has research facilities in Kansas City, MO. For additional information please visit

SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
6. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Frost & Sullivan is ... program addresses ways companies can innovate and transform ... --> ... --> ... well as the disrupting factors altering the industry, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module ... power of SICM to an AFM. , Park SICM benefits virtually all materials ...
(Date:12/1/2015)... , December 1, 2015 Dr. Harry Lander , President ... serving as Chief Science Officer and recruits five ... Harry Lander , President of Regen, expands his role to ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... a new closed system for isolating adipose-derived stem cells. The announcement starts a new ... adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 NXTD ... focused on the growing mobile commerce market and creator ... Gino Pereira , was recently interviewed on The ... air on this weekend on Bloomberg Europe , ... . --> NXTD ) ("NXT-ID" or the ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
Breaking Biology News(10 mins):